Image Image Image Image Image Image Image Image Image Image
Accessibilité
Haut de page

Up

ISEE2008: Phase III clinical trial in patients with dry AMD
18/11/2020

Identificació mitjançant SD-OCT d’una drusa que comença el procés d’atròfia. A) S’observa una drusa sense irregularitats, però amb hiper-reflectivitat en el RPE superposat. B) El RPE mostra irregularitats i punts hiper-reflectius per sobre. C) Els danys en el RPE són més evidents amb la presència de punts iso-reflectius — el drusen ooze. Recrutement


DESCRIPTION

ISEE2008 (GATHER2): A multicentre, randomised, double-masked, simulation controlled phase III clinical trial to assess the safety and efficacy of the intravitreal administration of Zimura (C5 complement inhibitor) in patients with geographic atrophy secondary to dry age-related macular degeneration

INCLUSION CRITERIA

Patients older than 50 with non-foveal geographic atrophy secondary to dry age-related macular degeneration. They should not have received prior treatment or have exudative macular degeneration in the other eye. Vision should be between 20/25 and 20/320.

AIMS

The aims of this study are to assess the safety and efficacy of the intravitreal administration of Zimura in patients with geographic atrophy secondary to dry age-related macular degeneration (AMD).

DURATION 
The duration of the study is 2 years.

 

Injections intravitréennesDMLA « sèche » ou atrophique
Last modified: 29 November, 2021 - 13:07